在患有外周动脉疾病的患者中,阿托瓦斯塔丁对克洛皮多格雷尔疗效的影响
Sasha P Suarez Ferreira1, Ryan P Hall1, Monica Majumdar1
1Division of Vascular and Endovascular Surgery, Massachusetts General Hospital, Boston, MA.
Annals of vascular surgery
|May 31, 2023
概括
阿托瓦斯塔丁可以通过降低血小板抑制来降低克洛皮多格雷尔的有效性. 服用这两种药物的患者可能需要替代性抗血小板治疗以获得足够的血栓预防.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 血管外科 血管外科
背景情况:
- 克洛皮多格雷尔和阿托瓦斯塔丁是由肝细胞P450酶代谢的.
- 阿托瓦斯塔丁可以抑制克洛皮多格雷尔的激活,可能降低其抗血小板作用并增加血栓形成的风险.
- 用血小板映射 (TEG-PM) 进行血小板显微镜可以评估微血管凝血和血小板功能.
研究的目的:
- 为了比较单独服用克洛皮多格雷尔和克洛皮多格雷尔与阿托瓦斯塔丁的患者的血小板功能.
- 为了研究影响皮多格雷尔治疗功效的潜在药物相互作用.
主要方法:
- 对接受外周再血管化治疗的患者进行前性观察研究 (2020年12月 - 2022年8月).
- 连续外科手术期间TEG-PM分析以评估血小板抑制.
- 单独服用克洛皮多格雷尔和服用克洛皮多格雷尔加阿托瓦斯塔丁的患者之间的血小板功能比较.
主要成果:
- 分析了72名患者 (31名单独使用克洛皮多格雷尔,41名克洛皮多格雷尔+阿托瓦斯塔丁).
- 单独服用克洛皮多格勒的患者表现出明显更大的血小板抑制 (49.01%) 与服用克洛皮多格勒+阿托瓦斯塔丁 (34.54%,P=0.03) 的患者相比.
- 阿司匹林的使用没有显著改变观察到的血小板抑制的差异.
结论:
- 同时使用阿托瓦斯塔丁与克洛皮多格雷尔可显著降低血小板抑制.
- 阿托瓦斯塔丁可能会干扰克洛皮多格雷尔的治疗效果,可能需要使用替代的抗血小板策略.
- 考虑阿托瓦斯塔丁治疗患者的替代抗血小板疗法,以确保充分的血栓预防.
相关概念视频
01:27Peripheral Artery Disease III: Interprofessional Care
14
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
14
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
570
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
570
01:27Coronary Artery Disease V: Interprofessional Care
12
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
12
01:26Peripheral Artery Disease IV: Nursing Management
15
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
15
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
225
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
225
01:26Atherosclerosis III: Management
16
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16